Novozymes A/S – ADR ( (NVZMY) ) has released its Q3 earnings. Here is a breakdown of the information Novozymes A/S – ADR presented to its investors.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Novonesis is a global leader in biosolutions, utilizing microbiology to innovate across more than 30 industries, enhancing production, consumption, and sustainability. The company has reported a robust 9% organic sales growth for the first nine months of 2024, with a particularly strong 11% in the third quarter. This performance is largely driven by their Food & Health Biosolutions and Planetary Health Biosolutions divisions, prompting an optimistic outlook for the full-year organic sales growth to reach the upper end of their 7-8% target.
The key highlights from Novonesis’s financial performance include an 8% growth in Food & Health Biosolutions and a 9% growth in Planetary Health Biosolutions. Specifically, Food & Beverages saw a 9% increase, while Household Care achieved a remarkable 15% growth. Regional performance was strong as well, with emerging markets reporting a 14% growth, significantly contributing to the overall positive results.
In developed markets, sales increased by 6%, led by Household Care and supported by Food & Beverages and Agriculture, Energy & Tech sectors. Meanwhile, emerging markets showed a robust 14% growth, driven by widespread demand across all areas. The company confirms its adjusted EBITDA margin between 35.5-36.5%, projecting continued strength into the year’s second half.
Looking ahead, Novonesis remains optimistic about its capacity to sustain growth and capitalize on its diversified portfolio and innovative strengths. With a solid foundation set by the recent performance, the company anticipates ongoing demand for its sustainable biosolutions, poised to deliver further value and innovation in the biosolutions industry.
